目前全球范围内并未有靶向HER3的药物成功获批上市。 根据智慧芽新药数据库信息,除HER3-DXD外,其余进入III期临床的靶向HER3药物分别为:Merus的双抗zenocutuzumab、百利天恒的双抗zalontamab以及百利天恒/SystImmune的EGFR/HER3双靶向ADC药物。其中,zenocutuzumab也已向FDA提交上市申请。 国内,除百利天恒,布局HER3...
● leela zero best> name ?NaN a Zero 0.15 Copyright (C) 2017-2018 Gian-Carlo Pascutto and contributors This program comes with ABSOLUTELY NO WARRANTY. This is free software, and you are welcome to redistribute it under certain conditions; see the COPYING file for details. ● leela zero ...